Parabolic Drugs is engaged in the manufacturing, including contract manufacturing, of APIs and API intermediates for the domestic market as well as for international markets, including regulated markets. It produces the Semi Synthetic Penicillin (SSP) and Cephalosporin range of antibiotics in oral and sterile form, along with their intermediate
The Indian pharmaceutical industry and the API segment are highly competitive. Stiff competition from new entrant (International as well domestic players) as well as introduction of new competing products in the API Industry. Adding to this, adequate availability of key raw materials at manageable price levels is critical and price fluctuations could intensify through competitive pricing pressures hampering margins. PDL also plans to enter into non-antibiotics and other niche therapeutic segments and continually expand its customer base which could be a significant challenge. Indian pharma industry consists of more than 20,000 manufacturers producing over 100,000 drugs. This Industry is technology driven, rapid advances in technology and scientific discoveries require up-gradations of the existing facilities to retain cost advantage.